0001493152-23-029634.txt : 20230821 0001493152-23-029634.hdr.sgml : 20230821 20230821163032 ACCESSION NUMBER: 0001493152-23-029634 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230821 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230821 DATE AS OF CHANGE: 20230821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rennova Health, Inc. CENTRAL INDEX KEY: 0000931059 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 680370244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35141 FILM NUMBER: 231189543 BUSINESS ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 561-855-1626 MAIL ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: CollabRx, Inc. DATE OF NAME CHANGE: 20120926 FORMER COMPANY: FORMER CONFORMED NAME: TEGAL CORP /DE/ DATE OF NAME CHANGE: 19950918 8-K 1 form8-k.htm
0000931059 false 0000931059 2023-08-21 2023-08-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 or 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): August 21, 2023

 

Rennova Health, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-35141   68-0370244
(Commission File Number)   (I.R.S. Employer Identification No.)

 

400 S. Australian Avenue, Suite 800, West Palm Beach,
Florida
  33401
(Address of Principal Executive Offices)   (Zip Code)

 

(561) 855-1626
(Registrant’s Telephone Number, Including Area Code)

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered under Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01. Regulation FD Disclosure

 

On August 21, 2023, Rennova Health, Inc. (the “Company”) issued a press release announcing that Seamus Lagan, our Chief Executive Officer, would be interviewed on Uptick Newswire’s “Stock Day” podcast with Kevin Davis. A copy of the press release is attached hereto as Exhibit 99.1 and a transcript of the interview is attached hereto as Exhibit 99.2.

 

The information furnished pursuant to this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits

 

  (d) Exhibits

 

Exhibit No.   Exhibit Description
     
99.1   Press Release dated August 21, 2023
     
99.2   Transcript of Interview of Seamus Lagan
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 21, 2023 RENNOVA HEALTH, INC.
     
  By: /s/ Seamus Lagan
    Seamus Lagan
    Chief Executive Officer
    (principal executive officer)

 

3

 

EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

RENNOVA HEALTH, INC. PROVIDES UPDATE AFTER FILING 2023 SECOND QUARTER FINANCIAL STATEMENTS

 

WEST PALM BEACH, Fla. (August 21, 2023) – Rennova Health, Inc. (OTC: RNVA) Chief Executive Officer Seamus Lagan recently joined Stock Day host Kevin Davis to provide an update after filing the 2023 second quarter financial statements and other information in its Form 10-Q with the SEC.

 

Davis began the interview by congratulating Lagan on the opening of a mental and behavioral health facility at its hospital and filing the Company’s second quarter 10-Q on time.

 

Davis went on to ask about what he saw as a fabulous recovery in revenues and profits and asked Lagan if the revenues of over $11 million and profits of over $2 million for the six months disclosed in the 10-Q was sustainable and further asked what the full year for 2023 might look like.

 

Lagan stated that he believed the revenues were sustainable and credited the management and employees with a continued focus on running an efficient operation which he expects to remain profitable. He continued to explain that the additional services being provided, and consistent patient volume, could mean revenues in excess of $20 million for 2023.

 

Davis followed by asking about the expectation for revenues from the recently opened 30 bed facility at the hospital campus by the Myrtle Recovery Centers, Inc. subsidiary, for alcohol and substance abuse services.

 

Lagan stated that it was good to see the facility opened and repeated that he believed this business would fit well with hospital operations. He went in to say that when operating at full potential this first facility for Myrtle should generate $4 - $5 million in profitable revenues a year.

 

Davis then mentioned the fast approaching year end and suggested that the Company could be leaving 2023 with annualized revenues in the $25-30 million range and be profitable. He asked Lagan how he intended to deliver continued growth and where he saw the Company a year from now.

 

 
 

 

Lagan responded that the current operations plus the behavioral health business should give the Company an annualized run rate of $25-30 million by year end. He went on to remind Davis that there were still some items to be fixed from previous more difficult days but explained the intention to formulate a plan before year end to duplicate the current model in the Jamestown facility in 2024, and stated that if that was successful it would be possible to leave 2024 with annualized revenues of $50-60 million. He confirmed his belief that this was achievable.

 

Davis ended the interview by asking Lagan what message he would like the Company’s shareholders to take away from the interview. Lagan responded by saying that he believed the Company was now delivering what it had hoped to deliver from work done over the past couple of years and stated a belief that there will be continued success and growth over the next couple of years.

 

To hear Seamus Lagan’s entire interview, follow the link to the podcast here:

https://audioboom.com/posts/8351331-rennova-health-inc-is-featured-on-the-stock-day-podcast

 

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/

 

About Rennova Health, Inc.

 

Rennova Health, Inc. (“Rennova,”) is a provider of health care services. The Company owns one operating hospital in Oneida, Tennessee known as Big South Fork Medical Center, a hospital located in Jamestown, Tennessee that it plans to reopen, a rural clinic in Kentucky and an alcohol and drug treatment facility operated by Myrtle Recovery Centers, Inc.

 

For more information, please visit www.rennovahealth.com

 

Forward-Looking Statements

 

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

 

Rennova Health

561-855-1626

info@rennovahealth.com

 

 

EX-99.2 3 ex99-2.htm

 

Exhibit 99.2

 

Rennova Health, Inc. (RNVA) Interview

CEO Seamus Lagan on Uptick Newswire – August 2023

 

Speakers: Kevin Davis and Seamus Lagan

 

Davis: On today’s show, we’re bringing back a returning company. The name of the company is Rennova Health, Inc. They trade on the OTC Exchange under the ticker symbol ‘RNVA’. With us today is the company’s CEO, Mr. Seamus Lagan. Seamus, welcome back to the podcast.

 

Lagan: Thanks, Kevin. I appreciate the opportunity to be here.

 

Davis: Seamus, congratulations on opening your behavioral health division and also congratulations on filing your second quarter financials on time. Let’s start with the financial statements. You have been consistent with your message that you could deliver a recovery and these results clearly demonstrate the best quarter you have had in a long time. Revenue for the year to date is in excess of $11 million and you have already generated just over $2 million in profits. That is a fabulous recovery. Now, here is the blunt question. Is it sustainable and what do you think the full year of 2023 will now look like?

 

Lagan: Thank you, Kevin. We firmly believe that current revenues are sustainable and we’re hopeful that we can continue to grow the current business with some additional services. The credit really must go to the management and the team of employees on the ground that manage the daily operations. They have continued to provide an excellent service to patients and remain focused on improving efficiencies across the board for us. With the recent addition of swing beds and an expectation for patient volume to remain at the current levels, I expect 2023 revenues to surpass $20 million and for operations to remain profitable.

 

Davis: Seamus, earlier in the week you announced that your subsidiary, Myrtle Recovery Centers, has now opened its first 30 patient facility for alcohol and substance abuse services at your hospital campus. We have previously spoken about Myrtle but can you remind us about why this works with your existing business, and can you also tell us about what revenues you expect from this business?

 

Lagan: It is great to have this facility open Kevin. It is good to see it now accepting patients. The business fits well with the hospital and it is a great use of space that we had available there. It will obviously take a few months to build the business to its full potential but once we get there, this first facility should generate $4 to $5 million of profitable revenues a year. That is quite exciting for us.

 

Davis: The last few months of the year are fast approaching, and it sounds like you could be leaving 2023 with annualized revenues in the $25 - $30 million range and be profitable. How do you plan to deliver continued growth in 2024 and where do you see this Company in another year from now?

 

 
 

 

Lagan: The current hospital and behavioral health business should give us a run rate of $25 to $30 million by year end as you suggest. We still have some things to fix from our more difficult days but we intend to formulate a plan before the year end to duplicate the current business model in our Jamestown property in 2024. Kevin, if we manage that and perhaps start with offering the behavioral health service and then add the critical access hospital model, it is totally possible that we leave 2024 with annualized revenues in the $50 to $60 million range. That’s the current goal and we believe that is achievable.

 

Davis: Folks, you’ve been listening to Seamus Lagan. He is the CEO of Rennova Health, Inc. They trade on the OTC Exchange under the ticker symbol ‘RNVA’. Seamus, before we part ways for today, what do you want to leave your shareholders with as a message from this interview?

 

Lagan: Kevin, I think that once again we have predicted this. We have worked hard for the last couple of years and I think we are delivering the results that we had hoped to deliver. I believe we can continue with this success and we can continue to grow this company, so I look forward to the next year or two and delivering some value for our shareholders.

 

Davis: Wonderful! Well we are definitely looking forward to getting updates from you in the future and can’t wait to talk to you then.

 

Lagan: Thank you very much, Kevin, appreciate it.

 

 

GRAPHIC 4 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 5 rnva-20230821.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 rnva-20230821_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 rnva-20230821_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 21, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 21, 2023
Entity File Number 001-35141
Entity Registrant Name Rennova Health, Inc.
Entity Central Index Key 0000931059
Entity Tax Identification Number 68-0370244
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 400 S. Australian Avenue
Entity Address, Address Line Two Suite 800
Entity Address, City or Town West Palm Beach
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33401
City Area Code (561)
Local Phone Number 855-1626
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000931059 2023-08-21 2023-08-21 iso4217:USD shares iso4217:USD shares 0000931059 false 8-K 2023-08-21 Rennova Health, Inc. DE 001-35141 68-0370244 400 S. Australian Avenue Suite 800 West Palm Beach FL 33401 (561) 855-1626 false false false false false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://rennovahealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm ex99-2.htm rnva-20230821.xsd rnva-20230821_lab.xml rnva-20230821_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 20 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "rnva-20230821_lab.xml" ] }, "presentationLink": { "local": [ "rnva-20230821_pre.xml" ] }, "schema": { "local": [ "rnva-20230821.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "RNVA", "nsuri": "http://rennovahealth.com/20230821", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://rennovahealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001493152-23-029634-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-029634-xbrl.zip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end